$2.895
-0.145[-4.77%]
Last update: 10:06AM Get Real Time Here
Allogene Therapeutics
(NASDAQ:ALLO)Latest News for Allogene Therapeutics Stock (NASDAQ:ALLO)
Allogene Therapeutics Stock (NASDAQ: ALLO)
Categories: All
Thursday, April 18, 2024
Tuesday, March 19, 2024
Friday, March 15, 2024
Thursday, March 14, 2024
- Recap: Allogene Therapeutics Q4 EarningsBenzinga Insights - Mar 14, 2024, 4:20PM
- Allogene Therapeutics Q4 2023 GAAP EPS $(0.51) Misses $(0.46) Estimate, Sales $21.000K Miss $23.571K EstimateBenzinga Newsdesk - Mar 14, 2024, 4:17PM
- Earnings Scheduled For March 14, 2024Benzinga Insights - Mar 14, 2024, 5:52AM
Wednesday, March 13, 2024
Tuesday, February 27, 2024
Monday, February 12, 2024
Friday, January 19, 2024
Friday, January 05, 2024
- Cell Therapy Focused Allogene Therapeutics' Resource Prioritization A Bold Move, Says AnalystVandana Singh - Jan 5, 2024, 2:32PM
- Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day SessionAvi Kapoor - Jan 5, 2024, 1:13PM
- Allogene Therapeutics shares are trading lower after the company announced its 2024 platform vision for the future of CAR T. Also, JMP Securities and Guggenheim downgraded their respective ratings on the stock.Benzinga Newsdesk - Jan 5, 2024, 11:43AM
- Guggenheim Downgrades Allogene Therapeutics to NeutralBenzinga Newsdesk - Jan 5, 2024, 9:36AM
- JMP Securities Downgrades Allogene Therapeutics to Market PerformBenzinga Newsdesk - Jan 5, 2024, 6:26AM
- Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market SessionAvi Kapoor - Jan 5, 2024, 6:19AM
Thursday, January 04, 2024
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga Insights - Jan 4, 2024, 4:31PM
- Allogene Therapeutics Partners With Foresight Diagnostics To Develop MRD-Based In-Vitro Diagnostic For Use In ALPHA3, For Frontline Consolidation In Large B-Cell LymphomaBenzinga Newsdesk - Jan 4, 2024, 4:18PM
- Allogene Therapeutics Says The Refined Approach Of The 2024 Platform Vision Results In A Streamlined Trial Footprint As Well As A Focused Pipeline Prioritization, Allowing The Company To Implement A Planned Restructuring Of Resources In Q1 2024Benzinga Newsdesk - Jan 4, 2024, 4:12PM
- Allogene Therapeutics Announces 2024 Platform Vision To Redefine The Future Of CAR T Led By ALPHA3, the Industry's First Pivotal Trial For Frontline Consolidation In Large B-Cell LymphomaBenzinga Newsdesk - Jan 4, 2024, 4:09PM
Tuesday, January 02, 2024
Friday, December 22, 2023
- Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day SessionAvi Kapoor - Dec 22, 2023, 1:28PM
- Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On FridayAvi Kapoor - Dec 22, 2023, 11:20AM
Friday, December 08, 2023
Wednesday, November 15, 2023
Friday, November 03, 2023
- Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day SessionLisa Levin - Nov 3, 2023, 1:26PM
- Allogene Therapeutics Presents Preclinical Data On Next Generation Cloak And Dagger Technologies At The Society For Immunotherapy Of Cancer Annual MeetingBenzinga Newsdesk - Nov 3, 2023, 12:05PM
- Allogene Therapeutics Presents Preclinical Data On A Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 At The Society For Immunotherapy Of Cancer Annual MeetingBenzinga Newsdesk - Nov 3, 2023, 12:05PM
- Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On FridayLisa Levin - Nov 3, 2023, 11:30AM
Thursday, November 02, 2023
Wednesday, November 01, 2023
Monday, October 16, 2023
Tuesday, October 03, 2023
Friday, September 29, 2023
Monday, September 25, 2023
Thursday, September 21, 2023
Tuesday, August 15, 2023
Monday, August 14, 2023
Tuesday, August 08, 2023
Monday, August 07, 2023
Thursday, August 03, 2023
- Allogene Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.Benzinga Newsdesk - Aug 3, 2023, 3:46PM
- Oppenheimer Reiterates Outperform on Allogene Therapeutics, Maintains $28 Price TargetBenzinga Newsdesk - Aug 3, 2023, 7:41AM
- EF Hutton Reiterates Buy on Allogene Therapeutics, Maintains $15 Price TargetBenzinga Newsdesk - Aug 3, 2023, 7:39AM